At a glance
ClinicalIndex Comparison RecordN/ACompleted· 33 enrolled
Drug / intervention
Lactobacillus rhamnosus GG +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial Testing a Probiotic Enteric Regimen for Easing Complications of Transplant (Randomized PERFECT Trial)
In Brief
A clinical study evaluating Lactobacillus rhamnosus GG and laboratory biomarker analysis was not performed because of no differences in the clinical outcomes for Graft Versus Host Disease. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This randomized pilot clinical trial studies Lactobacillus rhamnosus GG in reducing incidence of graft-versus-host disease in patients who have undergone donor stem cell transplant. Lactobacillus rhamnosus GG may be effective at preventing for graft-versus-host disease caused by a donor stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft Versus Host Disease
CountriesUnited States
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedMay 2014
Primary CompletionFeb 2016
Study CompletionFeb 2018
TodayJul 2026
First PostedMay 22, 2014
Enrollment StartFeb 18, 2013
Primary CompletionFeb 28, 2016
Study CompletionFeb 28, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.1 years ago
Interventions
Lactobacillus rhamnosus GGdietary
Given PO
laboratory biomarker analysis was not performed because of no differences in the clinical outcomesother
Correlative studies